Marcus Tan, MD
Surgical Oncology · Nashville, TNNPI 1467518266
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (51.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 93.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $6,703 and has fallen 85.1% since, to $1,001 in 2025.
Across 44 payments — averaging $179.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- AbbVie$150
- Dilon Technologies, Inc.$143
- Intera Oncology, Inc$101
- Sanofi-aventis U.S. LLC$72
- Boehringer Ingelheim$33
What the payments were for
- Travel & lodging$2,76535%
- Food & beverage$1,04013%
- Education$4,07252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 39 | $7,377 |
| AbbVie | 1 | $150 |
| Dilon Technologies, Inc. | 1 | $143 |
| Intera Oncology, Inc | 1 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Boehringer Ingelheim | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$4,000
- Da Vinci Surgical System$2,573
- HemoBlast Bellows$143
- Intera 3000 Implantable Pump$101
How this compares
$7,877 in reported general payments places this provider in the 80th percentile of 53 surgical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 37 | $115,701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $150 | $115,70137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 53 surgical oncology providers in Tennessee.
Other surgical oncology in Nashville
- Pat WhitworthNashville$62K
- Chandrasekhar PadmanabhanNashville$29K
- Mariana ChavezNashville$14K
- Kamran IdreesNashville$6K
- Colleen KiernanNashville$2K
- Deepa MaggeNashville$2K
- Ingrid MeszoelyNashville$2K
- Kristina ShafferNashville$1K
- Denise GarciaNashville$1K
- Tiffany NevillNashville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.